Biotech RadarJobs updated

COMPANY

Tvardi Therapeutics

HQ: Sugar Land, TX source · tvarditherapeutics.com ↗ · Southwest

Clinical Phase 2

Keywords: small molecule fibrosis oncology hepatocellular carcinoma Breast Cancer Idiopathic Pulmonary Fibrosis Head and Neck Squamous Cell Carcinoma Non Small Cell Lung Cancer Hepatocellular Cancer Colorectal Cancer Gastric Adenocarcinoma Melanoma chronic kidney disease TTI-101

Location: Sugar Land, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)1NIH grants

Timeline

  1. Trial start Phase 2: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis source ↗
  2. Trial start Phase 1/Phase 2: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma source ↗
  3. Trial start 1: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer source ↗
  4. Trial start Phase 1: Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT05384119Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer1TerminatedJan 9, 2023May 6, 2024 (actual)
NCT05671835Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisPhase 2CompletedMay 15, 2023Aug 14, 2025 (actual)
NCT05440708A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaPhase 1/Phase 2RecruitingMar 23, 2023Feb 1, 2027 (estimated)
NCT03195699Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced CancersPhase 1CompletedNov 15, 2017Jun 24, 2024 (actual)

NIH awards 1

Annual award amounts. Total $1.3M.

Feedback